US biotech firm Biogen Idec (Nasdaq: BIIB) has reported data confirming its Plegridy (peginterferon beta-1a) provides positive treatment effects that are maintained beyond the first year of the study in patients with relapsing multiple sclerosis.
Gilmore O’Neill, vice president of multiple sclerosis research and development at Biogen Idec, said: “These new, two-year data from ADVANCE further support the compelling efficacy and safety of Plegridy, providing physicians and patients with additional confidence in the benefits of using Plegridy to treat this chronic disease.”
Analysis of the study confirms that Plegridy’s positive effects on reducing disease activity and disability progression were maintained in year two. A significantly higher proportion of patients who took Plegridy for two years experienced no evidence of disease activity (defined as the absence of clinical and MRI disease activity over two years of treatment) compared to those who switched to Plegridy from placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze